English
简体中文
Total: £ 56.28
Published Date: 2025-08-08 | Pages: 122 | Tables: 129 | Pharma & Healthcare
The global Vaginitis Drug market size was US$ 2746 million in 2024 and is forecast to a readjusted size of US$ 4063 million by 2031 with a CAGR of 5.7% during the forecast period 2025-2031.
Vaginitis is an inflammation of the vaginal mucosa and submucosal connective tissue, and is a common disease in gynecological clinics. There are many types of vaginitis, and the main causes are external contamination, pathogen infection, etc. The drugs used for different types are different. There are generally two types of drugs for vaginitis: oral drugs (tablets) and topical drugs (topical suppositories/tablets, creams/gels, etc.). Specific drugs include metronidazole, clotrimazole, tinidazole, clindamycin, fluconazole, secnidazole, miconazole, ortacone, etc.
The global and Chinese vaginitis drug market has shown a significant growth trend in recent years. This change is due to the improvement of women's health awareness, the improvement of medical resources, and the gradual attention of social culture to gynecological health issues. Vaginitis, as a common gynecological disease, affects a large number of women around the world, and the market demand continues to increase, especially in some developing countries. With the promotion of public health policies and the popularization of health education, patients are increasingly aware of the early diagnosis and treatment of vaginitis. Therefore, the development potential of the vaginitis drug market is huge, which has attracted many pharmaceutical companies to increase their investment in research and development and production.
In the global market, the types of vaginitis drugs mainly include antifungal drugs, antibiotics, local therapeutic drugs (such as vaginal suppositories, gels, etc.) and some innovative drugs. These drugs are widely used in the treatment of bacterial vaginitis, fungal vaginitis, Trichomonas vaginitis and other diseases. Global leading pharmaceutical companies such as Pfizer, Johnson & Johnson, Bayer, etc. have launched a series of mature products and occupied market share through brand influence. At the same time, the rapid growth of emerging markets also provides expansion opportunities for international companies. Especially in developing countries, with the increase in women's health needs, pharmaceutical companies have increased their investment in these regions to promote market expansion.
In China, as the government pays more attention to women's health issues, the market for vaginitis drugs is also showing a rapid growth trend. Chinese women's health awareness is increasing year by year, especially the demand for vaginitis treatment among middle-aged and elderly women, pregnant women and postpartum women is gradually increasing. At the same time, the rapid development of Internet + medical and e-commerce platforms has made it more convenient to obtain vaginitis drugs, and online sales have become an important channel. Chinese local companies play an important role in this market. In addition to providing traditional antibiotics and antifungal drugs, many companies have also begun to develop safer and more effective innovative drugs to meet the diverse needs of the market.
The global Vaginitis Drug market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Pfizer
Bayer
Sanofi
Teva Pharmaceuticals
Sandoz
Prestige Consumer Healthcare
Lupin Pharmaceuticals
Bausch Health
Globela Pharma
Padagis
Galderma
Perrigo
Johnson & Johnson
Sinopharm Group
Tongfang Pharmaceuticals
Lukang Pharmaceuticals
Kelun Pharmaceuticals
Shandong Shijiazhuang Pharmaceutical Group
Livzon Pharmaceuticals
Wuhan Haite Biopharmaceuticals
Dare Bioscience
Conba
Luoxin Pharmaceuticals
Yuanda Pharmaceuticals
CR-Double Crane Pharmaceuticals
HCPC
Yunnan Baiyao
By Type: (Dominant Segment vs High-Margin Innovation)
External Drug
Oral Drug
By Application: (Core Demand Driver vs Emerging Opportunity)
Hospital Phamacy
Retail Phamacy
Online
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Pfizer in Europe)
- Emerging Product Trends: External Drug adoption vs. Oral Drug premiumization
- Demand-Side Dynamics: Hospital Phamacy growth in China vs. Retail Phamacy potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Vaginitis Drug market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Oral Drug in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Retail Phamacy in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Vaginitis Drug value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 External Drug
1.2.3 Oral Drug
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Phamacy
1.3.3 Retail Phamacy
1.3.4 Online
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Vaginitis Drug Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Vaginitis Drug Revenue Market Share by Region (2020-2025)
2.4 Global Vaginitis Drug Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Vaginitis Drug Market Size and Prospective (2020-2031)
2.5.2 Europe Vaginitis Drug Market Size and Prospective (2020-2031)
2.5.3 Asia-Pacific Vaginitis Drug Market Size and Prospective (2020-2031)
2.5.4 Latin America Vaginitis Drug Market Size and Prospective (2020-2031)
2.5.5 Middle East & Africa Vaginitis Drug Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Vaginitis Drug Historic Market Size by Type (2020-2025)
3.2 Global Vaginitis Drug Forecasted Market Size by Type (2026-2031)
3.3 Different Types Vaginitis Drug Representative Players
4 Breakdown Data by Application
4.1 Global Vaginitis Drug Historic Market Size by Application (2020-2025)
4.2 Global Vaginitis Drug Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Vaginitis Drug Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Vaginitis Drug Players by Revenue (2020-2025)
5.1.2 Global Vaginitis Drug Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Vaginitis Drug Revenue
5.4 Global Vaginitis Drug Market Concentration Analysis
5.4.1 Global Vaginitis Drug Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Vaginitis Drug Revenue in 2024
5.5 Global Key Players of Vaginitis Drug Head office and Area Served
5.6 Global Key Players of Vaginitis Drug, Product and Application
5.7 Global Key Players of Vaginitis Drug, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Vaginitis Drug Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Vaginitis Drug Market Size by Type (2020-2025)
6.1.2.2 North America Vaginitis Drug Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Vaginitis Drug Market Size by Application (2020-2025)
6.1.3.2 North America Vaginitis Drug Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Vaginitis Drug Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Vaginitis Drug Market Size by Type (2020-2025)
6.2.2.2 Europe Vaginitis Drug Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Vaginitis Drug Market Size by Application (2020-2025)
6.2.3.2 Europe Vaginitis Drug Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 Asia-Pacific Market: Players, Segments and Downstream
6.3.1 Asia-Pacific Vaginitis Drug Revenue by Company (2020-2025)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Vaginitis Drug Market Size by Type (2020-2025)
6.3.2.2 Asia-Pacific Vaginitis Drug Market Share by Type (2020-2025)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Vaginitis Drug Market Size by Application (2020-2025)
6.3.3.2 Asia-Pacific Vaginitis Drug Market Share by Application (2020-2025)
6.3.4 Asia-Pacific Market Trend and Opportunities
6.4 Latin America Market: Players, Segments and Downstream
6.4.1 Latin America Vaginitis Drug Revenue by Company (2020-2025)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Vaginitis Drug Market Size by Type (2020-2025)
6.4.2.2 Latin America Vaginitis Drug Market Share by Type (2020-2025)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Vaginitis Drug Market Size by Application (2020-2025)
6.4.3.2 Latin America Vaginitis Drug Market Share by Application (2020-2025)
6.4.4 Latin America Market Trend and Opportunities
6.5 Middle East & Africa Market: Players, Segments and Downstream
6.5.1 Middle East & Africa Vaginitis Drug Revenue by Company (2020-2025)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Vaginitis Drug Market Size by Type (2020-2025)
6.5.2.2 Middle East & Africa Vaginitis Drug Market Share by Type (2020-2025)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Vaginitis Drug Market Size by Application (2020-2025)
6.5.3.2 Middle East & Africa Vaginitis Drug Market Share by Application (2020-2025)
6.5.4 Middle East & Africa Market Trend and Opportunities
7 Key Players Profiles
7.1 Pfizer
7.1.1 Pfizer Company Details
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Vaginitis Drug Introduction
7.1.4 Pfizer Revenue in Vaginitis Drug Business (2020-2025)
7.1.5 Pfizer Recent Development
7.2 Bayer
7.2.1 Bayer Company Details
7.2.2 Bayer Business Overview
7.2.3 Bayer Vaginitis Drug Introduction
7.2.4 Bayer Revenue in Vaginitis Drug Business (2020-2025)
7.2.5 Bayer Recent Development
7.3 Sanofi
7.3.1 Sanofi Company Details
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Vaginitis Drug Introduction
7.3.4 Sanofi Revenue in Vaginitis Drug Business (2020-2025)
7.3.5 Sanofi Recent Development
7.4 Teva Pharmaceuticals
7.4.1 Teva Pharmaceuticals Company Details
7.4.2 Teva Pharmaceuticals Business Overview
7.4.3 Teva Pharmaceuticals Vaginitis Drug Introduction
7.4.4 Teva Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.4.5 Teva Pharmaceuticals Recent Development
7.5 Sandoz
7.5.1 Sandoz Company Details
7.5.2 Sandoz Business Overview
7.5.3 Sandoz Vaginitis Drug Introduction
7.5.4 Sandoz Revenue in Vaginitis Drug Business (2020-2025)
7.5.5 Sandoz Recent Development
7.6 Prestige Consumer Healthcare
7.6.1 Prestige Consumer Healthcare Company Details
7.6.2 Prestige Consumer Healthcare Business Overview
7.6.3 Prestige Consumer Healthcare Vaginitis Drug Introduction
7.6.4 Prestige Consumer Healthcare Revenue in Vaginitis Drug Business (2020-2025)
7.6.5 Prestige Consumer Healthcare Recent Development
7.7 Lupin Pharmaceuticals
7.7.1 Lupin Pharmaceuticals Company Details
7.7.2 Lupin Pharmaceuticals Business Overview
7.7.3 Lupin Pharmaceuticals Vaginitis Drug Introduction
7.7.4 Lupin Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.7.5 Lupin Pharmaceuticals Recent Development
7.8 Bausch Health
7.8.1 Bausch Health Company Details
7.8.2 Bausch Health Business Overview
7.8.3 Bausch Health Vaginitis Drug Introduction
7.8.4 Bausch Health Revenue in Vaginitis Drug Business (2020-2025)
7.8.5 Bausch Health Recent Development
7.9 Globela Pharma
7.9.1 Globela Pharma Company Details
7.9.2 Globela Pharma Business Overview
7.9.3 Globela Pharma Vaginitis Drug Introduction
7.9.4 Globela Pharma Revenue in Vaginitis Drug Business (2020-2025)
7.9.5 Globela Pharma Recent Development
7.10 Padagis
7.10.1 Padagis Company Details
7.10.2 Padagis Business Overview
7.10.3 Padagis Vaginitis Drug Introduction
7.10.4 Padagis Revenue in Vaginitis Drug Business (2020-2025)
7.10.5 Padagis Recent Development
7.11 Galderma
7.11.1 Galderma Company Details
7.11.2 Galderma Business Overview
7.11.3 Galderma Vaginitis Drug Introduction
7.11.4 Galderma Revenue in Vaginitis Drug Business (2020-2025)
7.11.5 Galderma Recent Development
7.12 Perrigo
7.12.1 Perrigo Company Details
7.12.2 Perrigo Business Overview
7.12.3 Perrigo Vaginitis Drug Introduction
7.12.4 Perrigo Revenue in Vaginitis Drug Business (2020-2025)
7.12.5 Perrigo Recent Development
7.13 Johnson & Johnson
7.13.1 Johnson & Johnson Company Details
7.13.2 Johnson & Johnson Business Overview
7.13.3 Johnson & Johnson Vaginitis Drug Introduction
7.13.4 Johnson & Johnson Revenue in Vaginitis Drug Business (2020-2025)
7.13.5 Johnson & Johnson Recent Development
7.14 Sinopharm Group
7.14.1 Sinopharm Group Company Details
7.14.2 Sinopharm Group Business Overview
7.14.3 Sinopharm Group Vaginitis Drug Introduction
7.14.4 Sinopharm Group Revenue in Vaginitis Drug Business (2020-2025)
7.14.5 Sinopharm Group Recent Development
7.15 Tongfang Pharmaceuticals
7.15.1 Tongfang Pharmaceuticals Company Details
7.15.2 Tongfang Pharmaceuticals Business Overview
7.15.3 Tongfang Pharmaceuticals Vaginitis Drug Introduction
7.15.4 Tongfang Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.15.5 Tongfang Pharmaceuticals Recent Development
7.16 Lukang Pharmaceuticals
7.16.1 Lukang Pharmaceuticals Company Details
7.16.2 Lukang Pharmaceuticals Business Overview
7.16.3 Lukang Pharmaceuticals Vaginitis Drug Introduction
7.16.4 Lukang Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.16.5 Lukang Pharmaceuticals Recent Development
7.17 Kelun Pharmaceuticals
7.17.1 Kelun Pharmaceuticals Company Details
7.17.2 Kelun Pharmaceuticals Business Overview
7.17.3 Kelun Pharmaceuticals Vaginitis Drug Introduction
7.17.4 Kelun Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.17.5 Kelun Pharmaceuticals Recent Development
7.18 Shandong Shijiazhuang Pharmaceutical Group
7.18.1 Shandong Shijiazhuang Pharmaceutical Group Company Details
7.18.2 Shandong Shijiazhuang Pharmaceutical Group Business Overview
7.18.3 Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Introduction
7.18.4 Shandong Shijiazhuang Pharmaceutical Group Revenue in Vaginitis Drug Business (2020-2025)
7.18.5 Shandong Shijiazhuang Pharmaceutical Group Recent Development
7.19 Livzon Pharmaceuticals
7.19.1 Livzon Pharmaceuticals Company Details
7.19.2 Livzon Pharmaceuticals Business Overview
7.19.3 Livzon Pharmaceuticals Vaginitis Drug Introduction
7.19.4 Livzon Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.19.5 Livzon Pharmaceuticals Recent Development
7.20 Wuhan Haite Biopharmaceuticals
7.20.1 Wuhan Haite Biopharmaceuticals Company Details
7.20.2 Wuhan Haite Biopharmaceuticals Business Overview
7.20.3 Wuhan Haite Biopharmaceuticals Vaginitis Drug Introduction
7.20.4 Wuhan Haite Biopharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.20.5 Wuhan Haite Biopharmaceuticals Recent Development
7.21 Dare Bioscience
7.21.1 Dare Bioscience Company Details
7.21.2 Dare Bioscience Business Overview
7.21.3 Dare Bioscience Vaginitis Drug Introduction
7.21.4 Dare Bioscience Revenue in Vaginitis Drug Business (2020-2025)
7.21.5 Dare Bioscience Recent Development
7.22 Conba
7.22.1 Conba Company Details
7.22.2 Conba Business Overview
7.22.3 Conba Vaginitis Drug Introduction
7.22.4 Conba Revenue in Vaginitis Drug Business (2020-2025)
7.22.5 Conba Recent Development
7.23 Luoxin Pharmaceuticals
7.23.1 Luoxin Pharmaceuticals Company Details
7.23.2 Luoxin Pharmaceuticals Business Overview
7.23.3 Luoxin Pharmaceuticals Vaginitis Drug Introduction
7.23.4 Luoxin Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.23.5 Luoxin Pharmaceuticals Recent Development
7.24 Yuanda Pharmaceuticals
7.24.1 Yuanda Pharmaceuticals Company Details
7.24.2 Yuanda Pharmaceuticals Business Overview
7.24.3 Yuanda Pharmaceuticals Vaginitis Drug Introduction
7.24.4 Yuanda Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.24.5 Yuanda Pharmaceuticals Recent Development
7.25 CR-Double Crane Pharmaceuticals
7.25.1 CR-Double Crane Pharmaceuticals Company Details
7.25.2 CR-Double Crane Pharmaceuticals Business Overview
7.25.3 CR-Double Crane Pharmaceuticals Vaginitis Drug Introduction
7.25.4 CR-Double Crane Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
7.25.5 CR-Double Crane Pharmaceuticals Recent Development
7.26 HCPC
7.26.1 HCPC Company Details
7.26.2 HCPC Business Overview
7.26.3 HCPC Vaginitis Drug Introduction
7.26.4 HCPC Revenue in Vaginitis Drug Business (2020-2025)
7.26.5 HCPC Recent Development
7.27 Yunnan Baiyao
7.27.1 Yunnan Baiyao Company Details
7.27.2 Yunnan Baiyao Business Overview
7.27.3 Yunnan Baiyao Vaginitis Drug Introduction
7.27.4 Yunnan Baiyao Revenue in Vaginitis Drug Business (2020-2025)
7.27.5 Yunnan Baiyao Recent Development
8 Vaginitis Drug Market Dynamics
8.1 Vaginitis Drug Industry Trends
8.2 Vaginitis Drug Market Drivers
8.3 Vaginitis Drug Market Challenges
8.4 Vaginitis Drug Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Vaginitis Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Vaginitis Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Vaginitis Drug Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Vaginitis Drug Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Vaginitis Drug Revenue Share by Region (2020-2025)
Table 6. Global Vaginitis Drug Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Vaginitis Drug Revenue Share Forecast by Region (2026-2031)
Table 8. Global Vaginitis Drug Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Vaginitis Drug Revenue Market Share by Type (2020-2025)
Table 10. Global Vaginitis Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Vaginitis Drug Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Vaginitis Drug Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Vaginitis Drug Revenue Market Share by Application (2020-2025)
Table 15. Global Vaginitis Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Vaginitis Drug Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Vaginitis Drug Application
Table 18. Global Vaginitis Drug Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Vaginitis Drug Market Share by Players (2020-2025)
Table 20. Global Top Vaginitis Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaginitis Drug as of 2024)
Table 21. Ranking of Global Top Vaginitis Drug Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Vaginitis Drug Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Vaginitis Drug, Headquarters and Area Served
Table 24. Global Key Players of Vaginitis Drug, Product and Application
Table 25. Global Key Players of Vaginitis Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Vaginitis Drug Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Vaginitis Drug Revenue Market Share by Company (2020-2025)
Table 29. North America Vaginitis Drug Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Vaginitis Drug Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Vaginitis Drug Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Vaginitis Drug Revenue Market Share by Company (2020-2025)
Table 33. Europe Vaginitis Drug Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Vaginitis Drug Market Size by Application (2020-2025) & (US$ Million)
Table 35. Asia-Pacific Vaginitis Drug Revenue by Company (2020-2025) & (US$ Million)
Table 36. Asia-Pacific Vaginitis Drug Revenue Market Share by Company (2020-2025)
Table 37. Asia-Pacific Vaginitis Drug Market Size by Type (2020-2025) & (US$ Million)
Table 38. Asia-Pacific Vaginitis Drug Market Size by Application (2020-2025) & (US$ Million)
Table 39. Latin America Vaginitis Drug Revenue by Company (2020-2025) & (US$ Million)
Table 40. Latin America Vaginitis Drug Revenue Market Share by Company (2020-2025)
Table 41. Latin America Vaginitis Drug Market Size by Type (2020-2025) & (US$ Million)
Table 42. Latin America Vaginitis Drug Market Size by Application (2020-2025) & (US$ Million)
Table 43. Middle East & Africa Vaginitis Drug Revenue by Company (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Vaginitis Drug Revenue Market Share by Company (2020-2025)
Table 45. Middle East & Africa Vaginitis Drug Market Size by Type (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Vaginitis Drug Market Size by Application (2020-2025) & (US$ Million)
Table 47. Pfizer Company Details
Table 48. Pfizer Business Overview
Table 49. Pfizer Vaginitis Drug Product
Table 50. Pfizer Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Bayer Company Details
Table 53. Bayer Business Overview
Table 54. Bayer Vaginitis Drug Product
Table 55. Bayer Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 56. Bayer Recent Development
Table 57. Sanofi Company Details
Table 58. Sanofi Business Overview
Table 59. Sanofi Vaginitis Drug Product
Table 60. Sanofi Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 61. Sanofi Recent Development
Table 62. Teva Pharmaceuticals Company Details
Table 63. Teva Pharmaceuticals Business Overview
Table 64. Teva Pharmaceuticals Vaginitis Drug Product
Table 65. Teva Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 66. Teva Pharmaceuticals Recent Development
Table 67. Sandoz Company Details
Table 68. Sandoz Business Overview
Table 69. Sandoz Vaginitis Drug Product
Table 70. Sandoz Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 71. Sandoz Recent Development
Table 72. Prestige Consumer Healthcare Company Details
Table 73. Prestige Consumer Healthcare Business Overview
Table 74. Prestige Consumer Healthcare Vaginitis Drug Product
Table 75. Prestige Consumer Healthcare Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 76. Prestige Consumer Healthcare Recent Development
Table 77. Lupin Pharmaceuticals Company Details
Table 78. Lupin Pharmaceuticals Business Overview
Table 79. Lupin Pharmaceuticals Vaginitis Drug Product
Table 80. Lupin Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 81. Lupin Pharmaceuticals Recent Development
Table 82. Bausch Health Company Details
Table 83. Bausch Health Business Overview
Table 84. Bausch Health Vaginitis Drug Product
Table 85. Bausch Health Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 86. Bausch Health Recent Development
Table 87. Globela Pharma Company Details
Table 88. Globela Pharma Business Overview
Table 89. Globela Pharma Vaginitis Drug Product
Table 90. Globela Pharma Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 91. Globela Pharma Recent Development
Table 92. Padagis Company Details
Table 93. Padagis Business Overview
Table 94. Padagis Vaginitis Drug Product
Table 95. Padagis Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 96. Padagis Recent Development
Table 97. Galderma Company Details
Table 98. Galderma Business Overview
Table 99. Galderma Vaginitis Drug Product
Table 100. Galderma Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 101. Galderma Recent Development
Table 102. Perrigo Company Details
Table 103. Perrigo Business Overview
Table 104. Perrigo Vaginitis Drug Product
Table 105. Perrigo Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 106. Perrigo Recent Development
Table 107. Johnson & Johnson Company Details
Table 108. Johnson & Johnson Business Overview
Table 109. Johnson & Johnson Vaginitis Drug Product
Table 110. Johnson & Johnson Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 111. Johnson & Johnson Recent Development
Table 112. Sinopharm Group Company Details
Table 113. Sinopharm Group Business Overview
Table 114. Sinopharm Group Vaginitis Drug Product
Table 115. Sinopharm Group Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 116. Sinopharm Group Recent Development
Table 117. Tongfang Pharmaceuticals Company Details
Table 118. Tongfang Pharmaceuticals Business Overview
Table 119. Tongfang Pharmaceuticals Vaginitis Drug Product
Table 120. Tongfang Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 121. Tongfang Pharmaceuticals Recent Development
Table 122. Lukang Pharmaceuticals Company Details
Table 123. Lukang Pharmaceuticals Business Overview
Table 124. Lukang Pharmaceuticals Vaginitis Drug Product
Table 125. Lukang Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 126. Lukang Pharmaceuticals Recent Development
Table 127. Kelun Pharmaceuticals Company Details
Table 128. Kelun Pharmaceuticals Business Overview
Table 129. Kelun Pharmaceuticals Vaginitis Drug Product
Table 130. Kelun Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 131. Kelun Pharmaceuticals Recent Development
Table 132. Shandong Shijiazhuang Pharmaceutical Group Company Details
Table 133. Shandong Shijiazhuang Pharmaceutical Group Business Overview
Table 134. Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Product
Table 135. Shandong Shijiazhuang Pharmaceutical Group Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 136. Shandong Shijiazhuang Pharmaceutical Group Recent Development
Table 137. Livzon Pharmaceuticals Company Details
Table 138. Livzon Pharmaceuticals Business Overview
Table 139. Livzon Pharmaceuticals Vaginitis Drug Product
Table 140. Livzon Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 141. Livzon Pharmaceuticals Recent Development
Table 142. Wuhan Haite Biopharmaceuticals Company Details
Table 143. Wuhan Haite Biopharmaceuticals Business Overview
Table 144. Wuhan Haite Biopharmaceuticals Vaginitis Drug Product
Table 145. Wuhan Haite Biopharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 146. Wuhan Haite Biopharmaceuticals Recent Development
Table 147. Dare Bioscience Company Details
Table 148. Dare Bioscience Business Overview
Table 149. Dare Bioscience Vaginitis Drug Product
Table 150. Dare Bioscience Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 151. Dare Bioscience Recent Development
Table 152. Conba Company Details
Table 153. Conba Business Overview
Table 154. Conba Vaginitis Drug Product
Table 155. Conba Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 156. Conba Recent Development
Table 157. Luoxin Pharmaceuticals Company Details
Table 158. Luoxin Pharmaceuticals Business Overview
Table 159. Luoxin Pharmaceuticals Vaginitis Drug Product
Table 160. Luoxin Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 161. Luoxin Pharmaceuticals Recent Development
Table 162. Yuanda Pharmaceuticals Company Details
Table 163. Yuanda Pharmaceuticals Business Overview
Table 164. Yuanda Pharmaceuticals Vaginitis Drug Product
Table 165. Yuanda Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 166. Yuanda Pharmaceuticals Recent Development
Table 167. CR-Double Crane Pharmaceuticals Company Details
Table 168. CR-Double Crane Pharmaceuticals Business Overview
Table 169. CR-Double Crane Pharmaceuticals Vaginitis Drug Product
Table 170. CR-Double Crane Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 171. CR-Double Crane Pharmaceuticals Recent Development
Table 172. HCPC Company Details
Table 173. HCPC Business Overview
Table 174. HCPC Vaginitis Drug Product
Table 175. HCPC Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 176. HCPC Recent Development
Table 177. Yunnan Baiyao Company Details
Table 178. Yunnan Baiyao Business Overview
Table 179. Yunnan Baiyao Vaginitis Drug Product
Table 180. Yunnan Baiyao Revenue in Vaginitis Drug Business (2020-2025) & (US$ Million)
Table 181. Yunnan Baiyao Recent Development
Table 182. Vaginitis Drug Market Trends
Table 183. Vaginitis Drug Market Drivers
Table 184. Vaginitis Drug Market Challenges
Table 185. Vaginitis Drug Market Restraints
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaginitis Drug Product Picture
Figure 2. Global Vaginitis Drug Market Share by Type: 2024 VS 2031
Figure 3. External Drug Features
Figure 4. Oral Drug Features
Figure 5. Global Vaginitis Drug Market Share by Application: 2024 VS 2031
Figure 6. Hospital Phamacy
Figure 7. Retail Phamacy
Figure 8. Online
Figure 9. Vaginitis Drug Report Years Considered
Figure 10. Global Vaginitis Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 11. Global Vaginitis Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Vaginitis Drug Revenue Market Share by Region: 2020 VS 2024
Figure 13. North America Vaginitis Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. Europe Vaginitis Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Asia-Pacific Vaginitis Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Latin America Vaginitis Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Middle East & Africa Vaginitis Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Global Vaginitis Drug Market Share by Players in 2024
Figure 19. Global Top Vaginitis Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaginitis Drug as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Vaginitis Drug Revenue in 2024
Figure 21. North America Vaginitis Drug Market Share by Type (2020-2025)
Figure 22. North America Vaginitis Drug Market Share by Application (2020-2025)
Figure 23. Europe Vaginitis Drug Market Share by Type (2020-2025)
Figure 24. Europe Vaginitis Drug Market Share by Application (2020-2025)
Figure 25. Asia-Pacific Vaginitis Drug Market Share by Type (2020-2025)
Figure 26. Asia-Pacific Vaginitis Drug Market Share by Application (2020-2025)
Figure 27. Latin America Vaginitis Drug Market Share by Type (2020-2025)
Figure 28. Latin America Vaginitis Drug Market Share by Application (2020-2025)
Figure 29. Middle East & Africa Vaginitis Drug Market Share by Type (2020-2025)
Figure 30. Middle East & Africa Vaginitis Drug Market Share by Application (2020-2025)
Figure 31. Pfizer Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 32. Bayer Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 33. Sanofi Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 34. Teva Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 35. Sandoz Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 36. Prestige Consumer Healthcare Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 37. Lupin Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 38. Bausch Health Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 39. Globela Pharma Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 40. Padagis Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 41. Galderma Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 42. Perrigo Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 43. Johnson & Johnson Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 44. Sinopharm Group Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 45. Tongfang Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 46. Lukang Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 47. Kelun Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 48. Shandong Shijiazhuang Pharmaceutical Group Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 49. Livzon Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 50. Wuhan Haite Biopharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 51. Dare Bioscience Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 52. Conba Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 53. Luoxin Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 54. Yuanda Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 55. CR-Double Crane Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 56. HCPC Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 57. Yunnan Baiyao Revenue Growth Rate in Vaginitis Drug Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
